Once-weekly survodutide safely tied to substantial weight loss in obese individuals: Study
Germany: In adults with a BMI of 27 kg/m2 or greater without diabetes, once-weekly survodutide produced significant reductions in body weight versus placebo from baseline to week 46, findings from a recent phase 2 trial have revealed. Survodutide’s tolerability profile was in line with what would be expected based on its mechanism of action; participants […]